Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients

Silvia Tenembaum1, Nestor Chamoles, Natalio Fejerman

  • 1Department of Neurology, Hospital Nacional de Pediatría Dr. J. P. Garrahan, Buenos Aires, Argentina. solier@ciudad.com.ar

Neurology
|October 23, 2002
PubMed

Insights

Childhood acute disseminated encephalomyelitis (ADEM) is typically benign, with most boys recovering well after treatment. Optic nerve involvement at onset is linked to disability, but ADEM can be distinguished from MS over time.

Area of Science:

  • Pediatric Neurology
  • Neuroimmunology
  • Demyelinating Diseases

Background:

  • Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system (CNS).
  • Limited pediatric studies exist, often with retrospective designs and short follow-up periods.

Purpose of the Study:

  • To characterize a cohort of pediatric ADEM patients.
  • To identify clinical and neuroimaging predictors of patient outcomes.

Main Methods:

  • Prospective study of 84 consecutive pediatric ADEM cases from 1988-2000.
  • Clinical assessment, neuroimaging (MRI), and cerebrospinal fluid (CSF) analysis were performed.
  • Long-term follow-up evaluated clinical course and disability (Expanded Disability Status Scale).

Main Results:

  • Mean age at onset was 5.3 years, with male predominance. Most cases (74%) followed viral illness or vaccination.
  • Prominent symptoms included hemiparesis (76%), long tract signs (85%), and altered mental state (69%).
  • High-dose corticosteroids, especially IV methylprednisolone, correlated with good recovery and MRI lesion resolution. 90% had a monophasic course; 11% had moderate to severe disability (EDSS 3-6.5).

Conclusions:

  • Childhood ADEM is generally a benign condition with a favorable prognosis, particularly in boys.
  • No MRI-defined groups predicted disability; optic nerve involvement at presentation was associated with poorer outcomes.
  • Long-term follow-up and CSF analysis (absence of oligoclonal bands) helped differentiate ADEM from multiple sclerosis (MS), even in relapsing cases.
Abstract